文献速递血脂与心血管预防冠心病

极高冠状动脉钙化(≥1000)与心血管疾病事件、非心血管结局及死亡率的关联:MESA研究结果

Very High Coronary Artery Calcium (≥1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality: Results From MESA.
PubMed 文献 · Circulation · 2021-03-02

本研究基于MESA前瞻性队列中6814名无已知心血管疾病的45-84岁多种族个体,平均随访13.6±4.4年,发现CAC≥1000者相比CAC 0和CAC 400-999,心血管事件、非心血管事件及全因死亡风险显著增高,其3点主要不良心血管事件年化发生率与FOURIER试验中稳定期二级预防人群相当。

要点

  • CAC≥1000者全因死亡风险较CAC 0增加1.94倍,心血管事件风险增加4.71倍。
  • CAC≥1000者3点MACE年化发生率为3.4/100人年,与FOURIER总人群的3.3相似。
  • CAC≥1000者非心血管事件风险亦显著增高,提示需关注非心血管结局。

核心结论

  • CAC≥1000个体是心血管事件、非心血管结局及死亡风险显著增高的人群,其3点MACE发生率与稳定治疗的二级预防人群相似。
  • 未来指南应考虑在指导积极预防性药物治疗时,对一级和二级预防患者采用更模糊的分层算法。

研究设计与样本

  • MESA为前瞻性、观察性、社区队列,纳入6814名45-84岁无已知心血管疾病的多种族个体,平均随访13.6±4.4年。
  • 采用Cox比例风险回归调整年龄、性别和传统危险因素,比较CAC≥1000与CAC 0及CAC 400-999的风险。
  • 使用性别调整对数模型计算MESA事件率,并与FOURIER临床试验安慰剂组稳定二级预防患者的事件率比较。

主要发现

  • 与CAC 400-999相比,CAC≥1000者(n=257)平均冠状动脉钙化血管数更多(3.4±0.5),总钙化面积更大(586.5±275.2 mm2),钙化密度相似,冠状动脉外钙化更广泛。
  • 完全调整后,CAC≥1000相比CAC 0的全因心血管事件、全冠心病事件、硬冠心病事件和全因死亡的风险比分别为4.71(3.63-6.11)、7.57(5.50-10.42)、4.86(3.32-7.11)和1.94(1.57-2.41)。
  • CAC≥1000相比CAC 400-999的上述四项风险比分别为1.65(1.25-2.16)、1.66(1.22-2.25)、1.51(1.03-2.23)和1.34(1.05-1.71)。
  • 随着CAC增加,所有事件类型的风险比均增加,未见明显CAC上限阈值。
  • CAC≥1000相比CAC 0和CAC 400-999,首次非心血管事件风险比分别为1.95(1.57-2.41)和1.43(1.12-1.83)。

临床怎么用

  • 对于CAC≥1000的一级预防个体,应视为心血管事件和死亡风险极高的人群,考虑强化预防性药物治疗。
  • CAC≥1000者的3点MACE风险与稳定二级预防人群相当,提示预防策略可参考二级预防的积极程度。
  • CAC≥1000者非心血管事件风险亦增高,临床管理中需综合关注非心血管结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on the unique cardiovascular disease (CVD), non-CVD, and mortality risks of primary prevention individuals with very high coronary artery calcium (CAC; ≥1000), especially compared with rates observed in secondary prevention populations. METHODS: Our study population consisted of 6814 ethnically diverse individuals 45 to 84 years of age who were free of known CVD from MESA (Multi-Ethnic Study of Atherosclerosis), a prospective, observational, community-based cohort. Mean follow-up time was 13.6±4.4 years. Hazard ratios of CAC ≥1000 were compared with both CAC 0 and CAC 400 to 999 for CVD, non-CVD, and mortality outcomes with the use of Cox proportional hazards regression adjusted for age, sex, and traditional risk factors. Using a sex-adjusted logarithmic model, we calculated event rates in MESA as a function of CAC and compared them with those observed in the placebo group of stable secondary prevention patients in the FOURIER clinical trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). RESULTS: Compared with CAC 400 to 999, those with CAC ≥1000 (n=257) had a greater mean number of coronary vessels with CAC (3.4±0.5), greater total area of CAC (586.5±275.2 mm2), similar CAC density, and more extensive extracoronary calcification. After full adjustment, CAC ≥1000 demonstrated a 4.71- (3.63-6.11), 7.57- (5.50-10.42), 4.86-(3.32-7.11), and 1.94-fold (1.57-2.41) increased risk for all CVD events, all coronary heart disease events, hard coronary heart disease events, and all-cause mortality, respectively, compared with CAC 0 and a 1.65- (1.25-2.16), 1.66- (1.22-2.25), 1.51- (1.03-2.23), and 1.34-fold (1.05-1.71) increased risk compared with CAC 400 to 999. With increasing CAC, hazard ratios increased for all event types, with no apparent upper CAC threshold. CAC ≥1000 was associated with a 1.95- (1.57-2.41) and 1.43-fold (1.12-1.83) increased risk for a first non-CVD event compared with CAC 0 and CAC 400 to 999, respectively. CAC 1000 corresponded to an annualized 3-point major adverse cardiovascular event rate of 3.4 per 100 person-years, similar to that of the total FOURIER population (3.3) and higher than those of the lower-risk FOURIER subgroups. CONCLUSIONS: Individuals with very high CAC (≥1000) are a unique population at substantially higher risk for CVD events, non-CVD outcomes, and mortality than those with lower CAC, with 3-point major adverse cardiovascular event rates similar to those of a stable treated secondary prevention population. Future guidelines should consider a less distinct stratification algorithm between primary and secondary prevention patients in guiding aggressive preventive pharmacotherapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Peng AW, Dardari ZA, Blumenthal RS, et al. Very High Coronary Artery Calcium (≥1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality: Results From MESA. Circulation. 2021. PMID: 33650435. doi:10.1161/CIRCULATIONAHA.120.050545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。